Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 40

Cited In for PubMed (Select 19410195)

1.

Gold(III)-pyrrolidinedithiocarbamato Derivatives as Antineoplastic Agents.

Nardon C, Chiara F, Brustolin L, Gambalunga A, Ciscato F, Rasola A, Trevisan A, Fregona D.

ChemistryOpen. 2015 Apr;4(2):183-91. doi: 10.1002/open.201402091. Epub 2015 Feb 19.

2.

Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.

Jeon YW, Kim RM, Lim ST, Choi HJ, Suh YJ.

J Breast Cancer. 2015 Mar;18(1):97-100. doi: 10.4048/jbc.2015.18.1.97. Epub 2015 Mar 27.

3.

Glomus tumor of the thenar eminence in neurofibromatosis type 1: case report and literature review.

Scaravilli G, Rossi R, Artiaco S, Merolla G.

Transl Med UniSa. 2014 Dec 19;11:63-8. eCollection 2015 Jan-Apr.

4.

Familial Lymphoproliferative Malignancies and Tandem Duplication of NF1 Gene.

Fernandes G, Souto M, Costa F, Oliveira E, Garicochea B.

Case Rep Oncol Med. 2014;2014:685857. doi: 10.1155/2014/685857. Epub 2014 Dec 14.

5.

Neurofibromatosis-related tumors: emerging biology and therapies.

Karajannis MA, Ferner RE.

Curr Opin Pediatr. 2015 Feb;27(1):26-33. doi: 10.1097/MOP.0000000000000169.

PMID:
25490687
6.

Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.

Wei J, Freytag M, Schober Y, Nockher WA, Mautner VF, Friedrich RE, Manley PW, Kluwe L, Kurtz A.

PLoS One. 2014 Oct 23;9(10):e107760. doi: 10.1371/journal.pone.0107760. eCollection 2014.

7.

TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.

Park GH, Lee SJ, Yim H, Han JH, Kim HJ, Sohn YB, Ko JM, Jeong SY.

Oncol Rep. 2014 Oct;32(4):1347-54. doi: 10.3892/or.2014.3379. Epub 2014 Aug 4.

8.

Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?

Pasmant E, Parfait B, Luscan A, Goussard P, Briand-Suleau A, Laurendeau I, Fouveaut C, Leroy C, Montadert A, Wolkenstein P, Vidaud M, Vidaud D.

Eur J Hum Genet. 2015 May;23(5):596-601. doi: 10.1038/ejhg.2014.145. Epub 2014 Jul 30.

PMID:
25074460
9.

The NF1 gene revisited - from bench to bedside.

Yap YS, McPherson JR, Ong CK, Rozen SG, Teh BT, Lee AS, Callen DF.

Oncotarget. 2014 Aug 15;5(15):5873-92.

10.

Oral metastasis of metaplastic breast carcinoma in a patient with neurofibromatosis 1.

Vivas AP, Bomfin LE, Pinto CA, Nicolau UR, Alves FA.

Case Rep Oncol Med. 2014;2014:719061. doi: 10.1155/2014/719061. Epub 2014 Apr 30.

11.

Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.

Watson AL, Anderson LK, Greeley AD, Keng VW, Rahrmann EP, Halfond AL, Powell NM, Collins MH, Rizvi T, Moertel CL, Ratner N, Largaespada DA.

Oncotarget. 2014 Mar 30;5(6):1502-14.

12.

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB.

Cancer Res. 2014 Apr 15;74(8):2340-50. doi: 10.1158/0008-5472.CAN-13-2625. Epub 2014 Feb 27.

13.

Spinal cord ependymoma associated with neurofibromatosis 1 : case report and review of the literature.

Cheng H, Shan M, Feng C, Wang X.

J Korean Neurosurg Soc. 2014 Jan;55(1):43-7. doi: 10.3340/jkns.2014.55.1.43. Epub 2014 Jan 31.

14.

MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.

Brundage ME, Tandon P, Eaves DW, Williams JP, Miller SJ, Hennigan RH, Jegga A, Cripe TP, Ratner N.

Oncogene. 2014 Dec 4;33(49):5626-36. doi: 10.1038/onc.2013.506. Epub 2014 Feb 10.

PMID:
24509877
15.

Compounds from Simarouba berteroana which inhibit proliferation of NF1-defective cancer cells.

Devkota KP, Wilson JA, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.

Phytochem Lett. 2014 Feb 1;7:42-45.

16.

'Particle genetics': treating every cell as unique.

Yvert G.

Trends Genet. 2014 Feb;30(2):49-56. doi: 10.1016/j.tig.2013.11.002. Epub 2013 Dec 6. Review.

17.

Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.

Chau V, Lim SK, Mo W, Liu C, Patel AJ, McKay RM, Wei S, Posner BA, De Brabander JK, Williams NS, Parada LF, Le LQ.

Cancer Res. 2014 Jan 15;74(2):586-97. doi: 10.1158/0008-5472.CAN-13-1934. Epub 2013 Nov 27.

18.

Cutaneous squamous cell carcinoma in a patient with neurofibromatosis type 1: A case report.

Ishida M, Okabe H.

Oncol Lett. 2013 Oct;6(4):878-880. Epub 2013 Jul 25.

19.

Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.

Peacock JD, Cherba D, Kampfschulte K, Smith MK, Monks NR, Webb CP, Steensma M.

J Transl Med. 2013 Sep 17;11:213. doi: 10.1186/1479-5876-11-213.

20.

The RASopathies.

Rauen KA.

Annu Rev Genomics Hum Genet. 2013;14:355-69. doi: 10.1146/annurev-genom-091212-153523. Epub 2013 Jul 15. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk